Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.

摘要

Primary central nervous system lymphoma (PCNSL) is an Epstein-Barr vims (EBV)-associated, acquired immunodeficiency syndrome (AIDS)-defining malignancy. Even in the HAART (highly active antiretroviral therapy) era, in which the survival of patients with PCNSL has improved and the incidence has sharply reduced [1, 2], the median survival time is <6 months [1]. PCNSL has become a rare disease and, consequently, there is no consensus and only anecdotal evidence on the best treatment. Options include high-dose methotrexate (MTX) and radiotherapy.